» Articles » PMID: 28695483

Diagnosis and Management of Treatment-refractory Hypothyroidism: an Expert Consensus Report

Overview
Publisher Springer
Specialty Endocrinology
Date 2017 Jul 12
PMID 28695483
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

There is a frequently encountered subset of hypothyroid patients who are refractory to standard thyroid hormone replacement treatment and require unexpectedly high doses of levothyroxine. In addition to clinical situations where hypothyroid patients are non-compliant, or where there is the possibility of excipient-induced disease exacerbation (gluten/celiac disease), therapeutic failure may be due to impaired absorption of the administered drug. The common approach to managing patients with unusual thyroxine needs is to escalate the dose of levothyroxine until targeted TSH levels are achieved. This approach can increase the risk for prolonged exposure to supratherapeutic doses of levothyroxine, which increase the chances of adverse outcomes. Repeated adjustments of levothyroxine can also escalate the costs of treatment, as frequent office visits and laboratory tests are required to determine and maintain the desired dose. Clinicians should take a systematic approach to managing patients whom they suspect of having treatment-refractory hypothyroidism. This may include searching for, and adjusting, occult medical conditions and/or other factors that may affect the absorption of levothyroxine, before up-titrating the dose of traditional levothyroxine therapy. Depending on the underlying pathology, another approach that may be considered is to try alternative formulations of levothyroxine that are less susceptible to intolerance issues related to excipients, or, in some cases, to malabsorption. The early discovery of these factors via a thoughtful patient work-up may avoid unnecessary thyroid medication adjustments and their consequences for both patients and clinicians.

Citing Articles

Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With "Refractory Hypothyroidism".

Caron P, Tudor C, Grunenwald S J Endocr Soc. 2025; 9(4):bvaf017.

PMID: 40046102 PMC: 11879399. DOI: 10.1210/jendso/bvaf017.


Thyroxine overuse and clinical indices guiding successful treatment withdrawal.

Livadas S, Angelopoulos N, Kollias A, Paparodis R, Androulakis I, Anagnostis P J Endocrinol Invest. 2025; .

PMID: 39899246 DOI: 10.1007/s40618-025-02543-2.


The association between primary frozen shoulder and serum lipids may be overestimated: evidence based on retrospective observational studies and Mendelian randomization.

Zhang Y, Fan W, Wang Y, Dong T, Liu D, Shao Y Front Endocrinol (Lausanne). 2025; 15:1363018.

PMID: 39882261 PMC: 11774719. DOI: 10.3389/fendo.2024.1363018.


Levothyroxine malabsorption following sleeve gastrectomy.

Gruneisen E, Yang J, Pasqua M Endocrinol Diabetes Metab Case Rep. 2025; 2025(1).

PMID: 39868565 PMC: 11811825. DOI: 10.1530/EDM-24-0115.


Rapid supervised levothyroxine absorption test in refractory hypothyroidism: suggestion for assessing absorption using two blood samples in low-resource settings.

Amiyangoda G, Antonypillai C, Gunatilake S, Weerathunge T, Ediriweera D, Kosgallana S Endocr Connect. 2024; 13(10).

PMID: 39158596 PMC: 11466281. DOI: 10.1530/EC-24-0277.


References
1.
Ain K, Refetoff S, Fein H, Weintraub B . Pseudomalabsorption of levothyroxine. JAMA. 1991; 266(15):2118-20. View

2.
Centanni M . Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine. 2012; 43(1):8-9. DOI: 10.1007/s12020-012-9814-9. View

3.
Beck-Peccoz P, Amr S, Faglia G, Weintraub B . Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med. 1985; 312(17):1085-90. DOI: 10.1056/NEJM198504253121703. View

4.
Trifiro G, Parrino F, Sultana J, Giorgianni F, Ferrajolo C, Bianchini E . Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice. Clin Drug Investig. 2015; 35(3):187-95. DOI: 10.1007/s40261-015-0271-0. View

5.
Suzuki Y, Takeshita E, Kano S, Hirata S, Sato S . [Impaired intestinal absorption of thyroid hormone in a case of Hashimoto's disease with anti-T3 and anti-T4 antibody]. Nihon Naibunpi Gakkai Zasshi. 1982; 58(12):1487-97. DOI: 10.1507/endocrine1927.58.12_1487. View